David Lavergne

879 total citations
18 papers, 581 citations indexed

About

David Lavergne is a scholar working on Molecular Biology, Nephrology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, David Lavergne has authored 18 papers receiving a total of 581 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 6 papers in Nephrology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in David Lavergne's work include Amyloidosis: Diagnosis, Treatment, Outcomes (17 papers), Parathyroid Disorders and Treatments (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). David Lavergne is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (17 papers), Parathyroid Disorders and Treatments (6 papers) and Neuroendocrine Tumor Research Advances (4 papers). David Lavergne collaborates with scholars based in France, Italy and United States. David Lavergne's co-authors include Arnaud Jaccard, Frank Bridoux, Dania Mohty, Sébastien Bender, Christophe Sirac, Corinne Lacombe, Éstelle Desport, Julie Abraham, Jean‐Paul Fermand and Jean‐Michel Goujon and has published in prestigious journals such as Blood, European Heart Journal and Haematologica.

In The Last Decade

David Lavergne

15 papers receiving 568 citations

Peers

Countries citing papers authored by David Lavergne

Since Specialization

Citations

This map shows the geographic impact of David Lavergne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lavergne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lavergne more than expected).

Fields of papers citing papers by David Lavergne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lavergne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lavergne. The network helps show where David Lavergne may publish in the future.

Co-authorship network of co-authors of David Lavergne

This figure shows the co-authorship network connecting the top 25 collaborators of David Lavergne. A scholar is included among the top collaborators of David Lavergne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lavergne. David Lavergne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study 2024 ·Amyloid ·Martin Nicol, (unknown), Mathilde Baudet, (unknown), Théo Pezel, David Lavergne, Arnaud Jaccard, Giuseppe Vergaro, (unknown), Michele Emdin, Stéphanie Harel, Bruno Royer, Alexis Talbot, V. Bousson, Laurent Macron, Bertrand Arnulf, Damien Logeart	0
2	Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome 2020 ·Blood ·Sébastien Bender, Vincent Javaugue, Alexis Saintamand, (unknown), Mehdi Alizadeh, (unknown), (unknown), Nathalie Gachard, David Lavergne, (unknown), Michel Cogné, Frank Bridoux, Christophe Sirac, Arnaud Jaccard	27
3	A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis 2020 ·Blood ·Murielle Roussel, Giampaolo Merlini, Sylvie Chevret, Bertrand Arnulf, Anne Marie Stoppa, Aurore Perrot, Giovanni Palladini, Lionel Karlin, Bruno Royer, Antoine Huart, Margaret Macro, Pierre Morel, Laurent Frenzel, Cyrille Touzeau, Eileen M. Boyle, Véronique Dorvaux, Fabien Le Bras, David Lavergne, Frank Bridoux, Arnaud Jaccard	87
4	A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results 2019 ·Clinical Lymphoma Myeloma & Leukemia ·Murielle Roussel, Bertrand Arnulf, Anne‐Marie Stoppa, Lionel Karlin, Aurore Perrot, Margaret Macro, Antoine Huart, Laurent Frenzel, Pierre Morel, Morten Salomo, Véronique Dorvaux, Giampaolo Merlini, Giovanni Palladini, David Lavergne, Bruno Royer, Frank Bridoux, Arnaud Jaccard	4
5	Diagnostic score of cardiac involvement in AL amyloidosis 2019 ·European Heart Journal - Cardiovascular Imaging ·Martin Nicol, Mathilde Baudet, S. Brun, Stéphanie Harel, Bruno Royer, Marguerite Vignon, Olivier Lairez, David Lavergne, Arnaud Jaccard, David Attias, Laurent Macron, Étienne Gayat, Alain Cohen‐Solal, Bertrand Arnulf, Damien Logeart	26
6	Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series 2019 ·American Journal of Hematology ·Jean‐Simon Rech, Bertrand Arnulf, Constance de Margerie‐Mellon, Alexis Talbot, Marion Malphettes, Marguerite Vignon, Bruno Royer, David Lavergne, Marianne Kambouchner, Véronique Meignin, Anne Bergeron, (unknown), Pierre‐Yves Brillet, Emmanuel Martinod, Frank Bridoux, Hilario Nunès, Arnaud Jaccard, Dominique Valeyre, Y. Uzunhan	8
7	Comparison of echocardiographic parameters in Fabry cardiomyopathy and light‐chain cardiac amyloidosis 2018 ·Echocardiography ·Josef Marek, Tomáš Paleček, Julien Magné, David Lavergne, (unknown), Bahaa M. Fadel, Arnaud Jaccard, Aleš Linhart, Dania Mohty	4
8	P1813Incidence and prevalence of light chain amyloidosis: a population-based study 2018 ·European Heart Journal ·Dania Mohty, (unknown), Julien Magné, David Lavergne, Dominique Bordessoule, Victor Aboyans, (unknown), Arnaud Jaccard	1
9	Présentation, survie et facteurs de survie de l’amylose respiratoire : une série multicentrique Française de 73 patients 2018 ·Revue des Maladies Respiratoires ·Jean‐Simon Rech, Bertrand Arnulf, Constance de Margerie‐Mellon, Marion Malphettes, M.R. Vignon, David Lavergne, Marianne Kambouchner, Véronique Meignin, Anne Bergeron, Grégoire Prévôt, Pierre‐Yves Brillet, Emmanuel Martinod, Dominique Valeyre, Arnaud Jaccard, Hilario Nunès, Y. Uzunhan	0
10	Left atrial function in patients with light chain amyloidosis: A transthoracic 3D speckle tracking imaging study 2017 ·Journal of Cardiology ·Dania Mohty, (unknown), Julien Magné, Bahaa M. Fadel, (unknown), (unknown), Chahrazed El Hamel, David Lavergne, Thibaud Damy, Victor Aboyans, Arnaud Jaccard	30
11	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 2017 ·Clinical Chemistry and Laboratory Medicine (CCLM) ·Giovanni Palladini, Arnaud Jaccard, Paolo Milani, David Lavergne, Andrea Foli, Sébastien Bender, Francesca Lavatelli, Tiziana Bosoni, Veronica Valentini, (unknown), Giovanni Ferraro, Marco Basset, Francesca Russo, Mario Nuvolone, Riccardo Albertini, Michel Cogné, Giampaolo Merlini	35
12	Identification of prognostic markers in transthyretin and AL cardiac amyloidosis* 2016 ·Amyloid ·Thibaud Damy, Arnaud Jaccard, Aziz Guellich, David Lavergne, Arnault Galat, Jean‐François Deux, Luc Hittinger, Jehan Dupuis, Valérie Molinier‐Frenkel, Charlotte Rigaud, Violaine Planté‐Bordeneuve, Diane Bodez, Dania Mohty	52
13	Hepatocyte growth factor measurement in AL amyloidosis 2015 ·Amyloid ·Julie Abraham, Éstelle Desport, (unknown), Benôıt Marin, Sébastien Bender, Corinne Lacombe, Stéphane Moreau, (unknown), Dominique Bordessoule, David Lavergne, Frank Bridoux, Arnaud Jaccard	8
14	Comparison and identification of early clinical, biological and echocardiographic prognostic markers in cardiac amyloidosis 2015 ·Orphanet Journal of Rare Diseases ·Thibaud Damy, Arnaud Jaccard, Aziz Guellich, David Lavergne, (unknown), Jehan Dupuis, Valérie Molinier‐Frenkel, Dania Mohty	3
15	Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) 2014 ·Haematologica ·Arnaud Jaccard, Raymond L. Comenzo, Parameswaran Hari, Philip N. Hawkins, Murielle Roussel, Pierre Morel, (unknown), Jean‐Luc Pellegrin, Estibaliz Lazaro, Dania Mohty, P. Mercié, (unknown), JD Gillmore, David Lavergne, Frank Bridoux, Ashutosh Wechalekar, (unknown)	85
16	AL Amyloidosis 2012 ·Orphanet Journal of Rare Diseases ·Éstelle Desport, Frank Bridoux, Christophe Sirac, Sébastien Delbès, Sébastien Bender, Béatrice Fernandez, Nathalie Quellard, Corinne Lacombe, Jean‐Michel Goujon, David Lavergne, Julie Abraham, Guy Touchard, Jean‐Paul Fermand, Arnaud Jaccard	166
17	Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex 2011 ·Amyloid ·(unknown), (unknown), (unknown), Éstelle Desport, Claire Aguilar, David Lavergne, (unknown), Xavier Leleu, (unknown), Brigitte Kolb, Frank Bridoux, Jean‐Paul Fermand, V. Leblond, (unknown)	3
18	Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis 2011 ·Archives of cardiovascular diseases ·Dania Mohty, Philippe Pîbarot, Jean G. Dumesnil, Nicole Darodes, David Lavergne, Najmeddine Echahidi, P Virot, Dominique Bordessoule, Arnaud Jaccard	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact